Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBT Margin (2016 - 2025)

Historic EBT Margin for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 20.27%.

  • Amicus Therapeutics' EBT Margin rose 154800.0% to 20.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83%, marking a year-over-year increase of 146800.0%. This contributed to the annual value of 5.44% for FY2024, which is 321400.0% up from last year.
  • As of Q3 2025, Amicus Therapeutics' EBT Margin stood at 20.27%, which was up 154800.0% from 12.4% recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' EBT Margin peaked at 20.27% during Q3 2025, and registered a low of 103.48% during Q1 2022.
  • Over the past 5 years, Amicus Therapeutics' median EBT Margin value was 39.48% (recorded in 2024), while the average stood at 42.34%.
  • In the last 5 years, Amicus Therapeutics' EBT Margin crashed by -155400bps in 2022 and then soared by 520400bps in 2023.
  • Amicus Therapeutics' EBT Margin (Quarter) stood at 97.74% in 2021, then grew by 19bps to 79.55% in 2022, then skyrocketed by 65bps to 27.51% in 2023, then surged by 119bps to 5.3% in 2024, then soared by 283bps to 20.27% in 2025.
  • Its last three reported values are 20.27% in Q3 2025, 12.4% for Q2 2025, and 14.41% during Q1 2025.